Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13814111 | 0.86 | KMT2A (0.47) | AKR1C3AKR1C2KMT2AKDM4EALDH1A1 | |
| SCHEMBL13802398 | 0.82 | KMT2A (0.59) | KMT2AKDM4EALDH1A1THRBBLM | |
| SCHEMBL13802421 | 0.80 | KMT2A (0.57) | AKR1C3AKR1C2PTGS1AKR1C4KMT2A | |
| SCHEMBL4205369 | 0.76 | ABCB1 (0.69) | AKR1C3AKR1C2PTGS1AKR1C4KMT2A | |
| SCHEMBL27474952 | 0.75 | AKR1C3 (0.59) | AKR1C3AKR1C2PTGS1AKR1C4KMT2A | |
| SCHEMBL4216463 | 0.74 | AKR1C3 (0.58) | AKR1C3AKR1C2PTGS1AKR1C4KMT2A | |
| SCHEMBL13802438 | 0.74 | ABCB1 (0.69) | AKR1C3AKR1C2PTGS1AKR1C4KMT2A | |
| SCHEMBL18133072 | 0.74 | AKR1C3 (0.81) | AKR1C3AKR1C2PTGS1AKR1C4AR | |
| SCHEMBL2467334 | 0.74 | CDC25A (0.54) | AKR1C3AKR1C2KDM4EALDH1A1MCL1 | |
| SCHEMBL28466412 | 0.73 | KMT2A (0.61) | AKR1C3AKR1C2PTGS1AKR1C4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | AKR1C3 570/4885AKR1C2 653/4885PTGS1 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.